A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients.
In a double-blind controlled study lasting 9 months, pipothiazine palmitate, a long-acting neuroleptic that can be administered intramuscularly once a month, was compared with fluphenazine enanthate in the maintenance treatment of 32 schizophrenic outpatients. Before the trial commenced, all patients were being treated with fluphenazine enanthate. The results indicate that pipothiazine palmitate was not as potent a neuroleptic as fluphenazine enanthate. Pipothiazine appears to resemble fluphenazine enanthate in its capacity to induce parkinsonism and tardive dyskinesia.
D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013843:Thiazines / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D014150:Antipsychotic Agents; D013843:Thiazines; D005476:Fluphenazine